Real-World Clinical Outcomes of Concurrent Chemotherapy and Dose-Escalated Twice-Daily Radiotherapy With Simultaneous Integrated Boost (SIB) for Limited-Stage Small Cell Lung Cancer

Lung Cancer

A Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy With Dose Escalation to 54 Gy With Concurrent Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Long-Term Results at a Single Institution

Clin Lung Cancer

Matsuura K, Komaki R, Kono M, Kudo T, Ono A, Kameoka T, Shintani I, Kusaba H, Kawakubo A, Ando Y, Nishihara K, Iwamoto Y, Shoda H, Katsuta T, Kagemoto M

doi: 10.1016/j.cllc.2025.09.003

Lung Cancer

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Lung Cancer

Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S

doi: 10.1016/j.lungcan.2025.108840

Lung Cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Adv Ther

Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S

doi: 10.1007/s12325-025-03408-z

RECOMMENDED

Lung Cancer

Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

Clin Lung Cancer

Kim D, Blocker S, Cavalieri CC, Cannon S, Cass AS, Olinger A, Bortka B, Gustafson B, Schepers A, Hobbs J, Blackwell L, Holman K, Widman W, Quick A, Grauer D, Lekkala MR, Huang C, Neupane P, Zhang J, Mullangi S, Schieber T

doi: 10.1016/j.cllc.2026.01.007

RECOMMENDED

Lung Cancer

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV

doi: 10.1016/j.esmoop.2025.106031

Lung Cancer

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Lung Cancer

Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G

doi: 10.1016/j.lungcan.2025.108762

RECOMMENDED

Lung Cancer

Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Aiba T, Hara S, Tominaga S, Yamamoto R, Sakashita H, Sakaguchi T, Ando Y, Koshio J, Takigami A, Maemondo M, Sugawara S

doi: 10.1016/j.lungcan.2026.109355

RECOMMENDED

Lung Cancer

Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer

Telli TA, Tatlı AM, Alan Ö, Keskin GY, Karadurmuş N, Karakaya S, Kaplan MA, Açıkgöz Ö, Bilici A, Mocan EE, Demirkazık A, Kahraman S, Şendur MA, Doğan M, Selam MT, Er Ö, Ünsal O, Yazıcı O, Özcan E, Kargı A, Gürbüz M, Selçukbiricik F, Şakalar T, Gürsoy P, Bilgin B, Selvi O, Karadağ İ, Eren OÖ, Bayram E, Sümbül AT, Keskin S, Öztürk A, Topçu S, Özen M, Kılıçkap S, Yumuk PF

doi: 10.1016/j.cllc.2025.07.015

Lung Cancer

Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use

Clin Lung Cancer

Joshi U, Ong F, Melzer D, Ma JC, Saltos A, Chiappori A, Creelan B, Pellini B, Lu C, Haura E, Shafique M, Tanvetyanon T, Kareem SS, Budhathoki P, Solarte DCB, Naqvi SMH, Puglianini OC, Gaballa S, Gray JE, Puri S

doi: 10.1016/j.cllc.2025.11.018

Related content

A Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy With Dose Escalation to 54 Gy With Concurrent Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Long-Term Results at a Single Institution

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer

Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group

Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use